ID: ALA5280008

Max Phase: Preclinical

Molecular Formula: C19H18BrN3O6S

Molecular Weight: 496.34

Associated Items:

Representations

Canonical SMILES:  NS(=O)(=O)c1ccc(N2CCC3(CC2)CC(=O)c2ccc(Br)cc2O3)c([N+](=O)[O-])c1

Standard InChI:  InChI=1S/C19H18BrN3O6S/c20-12-1-3-14-17(24)11-19(29-18(14)9-12)5-7-22(8-6-19)15-4-2-13(30(21,27)28)10-16(15)23(25)26/h1-4,9-10H,5-8,11H2,(H2,21,27,28)

Standard InChI Key:  LZYIJZSCAFQEKR-UHFFFAOYSA-N

Associated Targets(Human)

Carbonic anhydrase I 13240 Activities

Activity TypeRelationActivity valueUnitsAction TypeJournalPubMed IddoiAssay Aladdin ID

Carbonic anhydrase II 17698 Activities

Activity TypeRelationActivity valueUnitsAction TypeJournalPubMed IddoiAssay Aladdin ID

Carbonic anhydrase VII 2318 Activities

Activity TypeRelationActivity valueUnitsAction TypeJournalPubMed IddoiAssay Aladdin ID

Carbonic anhydrase IX 8255 Activities

Activity TypeRelationActivity valueUnitsAction TypeJournalPubMed IddoiAssay Aladdin ID

Molecule Features

Natural Product: NoOral: NoChemical Probe: NoParenteral: No
Molecule Type: Topical: NoFirst In Class: NoBlack Box: No
Chirality: NoAvailability: NoProdrug: No

Drug Indications

MESH IDMESH Heading EFO IDsEFO TermsMax Phase for IndicationReferences

Mechanisms of Action

Mechanism of ActionAction Typetarget IDTarget NameTarget TypeTarget OrganismBinding Site NameReferences

Properties

Molecular Weight: 496.34Molecular Weight (Monoisotopic): 495.0100AlogP: 3.01#Rotatable Bonds: 3
Polar Surface Area: 132.84Molecular Species: NEUTRALHBA: 7HBD: 1
#RO5 Violations: 0HBA (Lipinski): 9HBD (Lipinski): 2#RO5 Violations (Lipinski): 0
CX Acidic pKa: 10.23CX Basic pKa: CX LogP: 2.47CX LogD: 2.47
Aromatic Rings: 2Heavy Atoms: 30QED Weighted: 0.51Np Likeness Score: -1.20

References

1. Ghatpande NG, Jadhav JS, Kaproormath RV, Soliman ME, Shaikh MM..  (2020)  A brief overview on recent advances in spiro[chromane-2,4'-piperidine]-4(3H)-one-functionalized compounds in medicinal chemistry research.,  28  (23.0): [PMID:33069128] [10.1016/j.bmc.2020.115813]

Source